Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

255 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the efficacy and safety of GW05 administered in 3 regimens versus metronidazole 0.75% for the treatment of bacterial vaginosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Persistence of Bacterial Vaginosis

NCT00741845

Bacterial Vaginosis

TERMINATED PHASE3

Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network

NCT00503542

Vaginitis

COMPLETED EARLY_PHASE1

Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age

NCT06458543

Bacterial Vaginosis

RECRUITING PHASE4

Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

NCT03954990

Bacterial Vaginoses

TERMINATED PHASE1

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689

BACTERIAL VAGINOSIS Signs and Symptoms to be Evaluated and Recorded Include Vaginal Discharge Color, Odor, and Consistency +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, randomized, investigator-blinded, phase 2, dose ranging study of GW05 vaginal gel administered in 3 regimens compared to metronidazole 0.75% (QD x 5 days) for the treatment of bacterial vaginosis. Subjects will be evaluated at three timepoints (1 screening/baseline visit, post-treatment phone call and 1 test-of-cure visit). The total study duration may be up to 30 days for a subject.

Study medication will be applied intravaginally once daily at bedtime according to the assigned dosing schedule using the supplied 5-gram vaginal applicators.

Investigator blinding will be ensured by utilizing an independent drug dispensing coordinator at each site.

Bacterial vaginosis (BV) is an infection of the vagina (birth canal) that is the result of an overgrowth of bacteria that are often normally found in the vagina. This type of vaginal infection typically does not cause irritation. The most common complaint of patients who suffer from BV is a fishy-smelling vaginal discharge. The amount of vaginal discharge may or may not be increased above a normal discharge. The bad odor may get worse after sexual intercourse or during the menstrual period. BV is also strongly associated with problems during pregnancy, such as premature (early) birth, and with an increased risk of sexually transmitted diseases. Therefore, it is important to treat the infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginosis, Bacterial Vaginal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

vaginal gel once daily regimen A

Intervention Type DRUG

GW05

vaginal gel once daily regimen B

Intervention Type DRUG

GW05

vaginal gel once daily regimen C

Intervention Type DRUG

Metronidazole

vaginal gel 0.75% once daily for 5 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females at least 18 years of age
* In good general health
* Confirmed current diagnosis of bacterial vaginosis (determined at study screening)
* Negative pregnancy test (for women who are able to become pregnant)
* Must abstain from sexual intercourse throughout the first 7 days of thes study
* Must abstain from alcohol ingestion during the treatment period and for one day afterward
* Must not use intra-vaginal products for the duration of the study

Exclusion Criteria

* Pregnant, lactating, or planning to become pregnant during the study period
* Menstruating at the time of the diagnosis or anticipate the onset of menses during the treatment phase of the study
* Had a medical event within 90 days of the visit (e.g., stroke, heart attack, etc.)
* Received specific treatments/medications /therapy within the designated time period prior to study enrollment

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No